key: cord-0980335-rbyzeyno
authors: Koutsoukis, Athanasios; Delmas, Clément; Roubille, François; Bonello, Laurent; Schurtz, Guillaume; Manzo-Silberman, Stéphane; Puymirat, Etienne; Elbaz, Meyer; Bouisset, Frédéric; Meunier, Pierre-Alain; Huet, Fabien; Paganelli, Franck; Laine, Marc; Lemesle, Gilles; Lamblin, Nicolas; Henry, Patrick; Tea, Victoria; Gallet, Romain; Teiger, Emmanuel; Huguet, Raphaëlle; Fard, Damien; Lim, Pascal
title: Acute Coronary Syndromes in the Era of SARS-CoV-2 Infection: A Registry of the French Group of Acute Cardiac Care
date: 2020-11-11
journal: CJC Open
DOI: 10.1016/j.cjco.2020.11.003
sha: c0127b9f7c028a8945863f54d871c204889f9ac1
doc_id: 980335
cord_uid: rbyzeyno

BACKGROUND: We aimed to report clinical characteristics and outcomes of patients with and without SARS-CoV-2 infection referred for acute coronary syndrome (ACS) during the peak of the pandemic in France. METHODS: We included all consecutive patients referred for ST-elevation myocardial infarction (STEMI) or NSTEMI during the first 3 weeks of April 2020 in 5 university hospitals (Paris, south and north of France), all performing primary percutaneous coronary intervention (PCI). RESULTS: The study included 237 patients (67±14, 69% of male), 116 (49%) with STEMI and 121 (51%) with NSTEMI. The prevalence of SARS-CoV-2 associated ACS was 11% (n=26) and 11 patients had severe hypoxemia on presentation (mechanical ventilation or nasal oxygen >6L/min). Patients were comparable regarding medical history and risk factors, except a higher prevalence of diabetes mellitus in SARS-CoV-2 patients (53.8% vs 25.6%, p=0.003). In SARS-CoV-2 patients, cardiac arrest on admission was more frequent (26.9% vs. 6.6%, p<0.001). The presence of significant coronary artery disease and culprit artery occlusion in SARS-CoV-2 patients, was 92% and 69.4% for STEMI, 50% and 15.5% for NSTEMI. PCI was performed in the same percentage of STEMI (84.6%) and NSTEMI (84.8%) cases, regardless of SARS-CoV-2 infection, but no-reflow (19.2% vs. 3.3%, p<0.001) was greater in SARS-CoV-2 patients. In-hospital death occurred in 7 SARS-CoV-2 patients (5 from cardiac cause) and was higher compared to non-infected patients (26.9% vs 6.2%, p<0.001) CONCLUSIONS: In this registry, ACS in SARS-CoV-2 patients presented with high percentage of cardiac arrest on admission, high incidence of no-reflow and high in-hospital mortality.

Background: We aimed to report clinical characteristics and outcomes of patients with and without SARS-CoV-2 infection referred for acute coronary syndrome (ACS) during the peak of the pandemic in France.

We included all consecutive patients referred for ST-elevation myocardial infarction (STEMI) or NSTEMI during the first 3 weeks of April 2020 in 5 university hospitals (Paris, south and north of France), all performing primary percutaneous coronary intervention (PCI).

The study included 237 patients (67±14, 69% of male), 116 (49%) with STEMI and 121 (51%) with NSTEMI. The prevalence of SARS-CoV-2 associated ACS was 11% (n=26) and 11 patients had severe hypoxemia on presentation (mechanical ventilation or nasal oxygen >6L/min). Patients were comparable regarding medical history and risk factors, except a higher prevalence of diabetes mellitus in SARS-CoV-2 patients (53.8% vs 25.6%, p=0.003). In SARS-CoV-2 patients, cardiac arrest on admission was more frequent (26.9% vs. 6.6%, p<0.001). The presence of significant coronary artery disease and culprit artery occlusion in SARS-CoV-2 patients, was 92% and 69.4% for STEMI, 50% and 15.5% for NSTEMI. PCI was performed in the same percentage of STEMI (84.6%) and NSTEMI (84.8%) cases, regardless of SARS-CoV-2 infection, but no-reflow (19.2% vs. 3.3%, p<0.001) was greater in SARS-CoV-2 patients. In-hospital death occurred in 7 SARS-CoV-2 patients (5 from cardiac cause) and was higher compared to non-infected patients (26.9% vs 6.2%, p<0.001)

In this registry, ACS in SARS-CoV-2 patients presented with high percentage of cardiac arrest on admission, high incidence of no-reflow and high in-hospital mortality. with a wide spectrum of presentations and associated mortality of 2-3% 1,2 . The disease is characterized first by a viral replication phase (early infection) followed by a host inflammatory response phase related to a cytokine storm, which may be accompanied by thrombotic events. For example, pulmonary embolism prevalence is reported to be around 40% among patients with SARS-CoV-2-associated pneumonia, with predominantly bilateral vascular defects, which may suggest a pro-thrombotic state 3, 4 . Data in literature report a cardiac involvement in 20% of severe SARS-CoV-2 infections, which translates into worsened outcome. Underlying pathophysiological mechanisms remain poorly understood and may involve coronary thrombosis and/or acute viral and immuno-inflammatory myocarditis [5] [6] [7] . The recent case series by Bangalore et al that presented 18 patients presenting with SARS-CoV-2 infection and ST-segment elevation on electrocardiogram showed a surprisingly high in-hospital mortality rate, i.e. 72%, contrary to the reported event rates for acute coronary syndromes (ACS) in recent literature (between 4 to 12%) 8, 9 . Also in the case series of Stefanini et al from Italy, in approximately 40% of patients with COVID-19 and STEMI, a culprit lesion was not identifiable by coronary angiography. 10 were screened. All patients with myocardial infarction (STEMI or NSTEMI) that underwent coronary angiogram were included in the study. Myocardial infarction was defined as rise and/or fall of troponin values with at least one value above the 99 th percentile and clinical evidence of acute myocardial ischemia (symptoms of myocardial ischemia, new ischemic ECG changes, development of pathological Q waves, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology or identification of a coronary thrombus by coronary angiography) 11 . STEMI was diagnosed when ST-segment elevation ≥1 mm was seen in at least 2 contiguous leads in any location on the index or qualifying ECG, or when presumed new left bundle-branch block or documented new Q waves were observed. In the absence of ST-segment elevation, patients meeting the inclusion criteria were considered to have NSTEMI. We excluded patients medically treated without coronary angiogram documentation. Although all consecutive patients were screened, data collection was retrospective. Table 1) were included in the registry, of whom 49% (n=116) were admitted for STEMI and 51% (n=121) for NSTEMI. SARS-CoV-2 infection was reported in 26 patients (17 with STEMI and 9 with NSTEMI). Patients with SARS-CoV-2 were found to be more frequently diabetic (54% vs. 26%, p=0.003) and tended to have greater body mass index (28±4 vs. 26±5 kg/m², p=0.07, Table 1 ). The rate of ACS with SARS-CoV-2 infection was higher for Paris (19%) compared to the other centers (9% in the north of France and 7% in the south of France). The Table S1 ).

NSTEMI: SARS-CoV-2 infection was reported in 9/121 (7.4%) patients admitted for NSTEMI. NSTEMI with and without SARS-CoV-2 infection had similar age and gender distribution (Table 3) . Similarly to STEMI population, cardiac arrest on presentation tended to be more frequent in patients with SARS-CoV-2 infection (11% vs. 2%, p=0.08). No J o u r n a l P r e -p r o o f differences were observed in ACS treatment between the SARS-CoV-2 and non-SARS-CoV-2 group [ 89% vs 92% for aspirin, 78% vs 80% for P2Y12 inhibitors, 67% vs 77% for heparin]. However, GP IIb/IIIa inhibitors was used more frequently in NSTEMI with than without SARS-CoV-2 (25% vs. 3%, p=0.05). Non obstructive coronary artery disease was reported in only one NSTEMI with SARS-CoV-2 infection. In NSTEMI with significant coronary lesion, occlusion of the culprit artery was more frequent in patients with SARS-CoV-2 infection (50% vs. 16%, p=0.015). PCI rate was similar in the two groups. Cardiac troponin levels and LVEF were similar between the two groups. In-hospital cardiac arrest (33% vs 5%, p=0.007) was more frequent in NSTEMI with SARS-CoV-2 infection but no death was reported in NSTEMI with SARS-CoV-2 (Table 3 and Supplementary table S1) . 

SARS-CoV-2 infection, there was no significant difference in time from symptom onset to revascularization. Also, compared to the data of the French registry on ACS (FAST-MI), the pandemic did not seem to influence the median time from symptom onset to revascularization (4 hours vs 3.8 hours) 14 . This lack of difference was probably due to the efficient reinforcement of the French EMS (SAMU) during the epidemic crisis. In terms of coronary anatomy, SARS-CoV-2 patients had MINOCA more frequently but the majority had obstructive coronary artery disease with a high prevalence of an acutely occluded culprit artery both in STEMI and NSTEMI patients. This may explain the high proportion of cardiac arrest in this population. 

infection had a dramatically higher in-hospital mortality (42.1%) than patients with STEMI without SARS-CoV-2 infection (8.1%). These rates are also higher than those reported in the FAST-MI registry (approximately 2.8%) 18 because ACS with early death were excluded from the FAST-MI registry. It may be tempting to consider that the excess mortality in ACS with concomitant SARS-CoV-2 infection is driven by the respiratory infection but our present registry shows that hemodynamic complications (cardiac arrest and heart failure) were highly prevalent in the SARS-CoV-2 group and that independent variables associated with death were cardiac arrest at presentation and no-reflow. Almost half (43%, n=3/7) deaths in SARS-CoV-2 group had non severe respiratory infection and died from cardiovascular complications.

Altogether, these data underline the importance of referring the majority of patients with ACS and SARS-CoV-2 infection to coronary angiogram, because the vast majority of STEMI with concomitant SARS-CoV-2 infection had a significant coronary lesion that could be treated by PCI. These findings are also consistent in the NSTEMI population as 90% of patients in SARS-CoV-2 group had a significant coronary disease with a high proportion of J o u r n a l P r e -p r o o f culprit artery occlusion. The low proportion of NSTEMI in SARS-CoV-2 patients is possibly related to the fact that SARS-CoV-2 patients with NSTEMI are under-reported and usually not referred to coronary angiogram. Increase in cardiac biomarkers has been considered as a sign of myocardial injury related to systemic inflammation, cytokine storm, or other immunologic mechanisms. However, given the high rate of significant coronary thrombosis, coronary angiogram should be systematically considered, especially in patients with hemodynamic instability.

Although this registry managed to gather significant data from multiple centers in a very short period of time, the sample size remains small. Larger studies are needed in order to precisely describe the relationship between SARS-CoV-2 infection, ACS occurrence and prognosis.

Moreover, the prevalence of SARS-CoV-2 related ACS might be overestimated for two reasons. First, some of the participating hospitals were reference centers for the SARS-CoV-2 infection, in regions with high SARS-CoV-2 prevalence during the study period. Second, published data from regions with a high SARS-CoV-2 prevalence suggest a significant decrease in ACS-related hospitalizations during the pandemic 19 . The effect of the SARS-CoV-2 in the overall ACS prevalence in the corresponding population was beyond the scope of this study. 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Findings of Acute Pulmonary Embolism in COVID-19 Patients

COVID-19 Complicated by Acute Pulmonary Embolism

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol

COVID-19 and the Heart

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

ST-Segment Elevation in Patients with Covid-19 -A Case Series

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes

Fourth universal definition of myocardial infarction

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the

The Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase I Findings

Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to

High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction

Pulmonary, Cerebral, and Renal Thromboembolic Disease Associated with COVID-19 Infection

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

French Registry on Acute ST-elevation and non−STelevation Myocardial Infarction 2015 (FAST-MI 2015). Design and baseline data

Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy